EpCAM aptamer-mediated survivin silencing sensitized cancer stem cells to doxorubicin in a breast cancer model

Theranostics

Volumn 5, Issue 12, 2015, Pages 1456-1472

  Wang, Tao ^a,b   Gantier, Michael P ^c,d   Xiang, Dongxi ^b   Bean, Andrew G ^e   Bruce, Matthew ^e   Zhou, Shu Feng ^f   Khasraw, Mustafa ^b   Ward, Alister ^b   Wang, Li ^a   Wei, Ming Q ^g   AlShamaileh, Hadi ^b   Chen, Lijue ^b   She, Xiaodong ^b   Lin, Jia ^h   Kong, Lingxue ^b   Shigdar, Sarah ^b   Duan, Wei ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b DEAKIN UNIVERSITY   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e CSIRO   (Australia)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g GRIFFITH UNIVERSITY   (Australia)

^h SICHUAN UNIVERSITY   (China)

Author keywords

Aptamer; Breast cancer; Cancer stem cell; RNA interference; Survivin

Indexed keywords

APTAMER; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CELL ADHESION MOLECULE; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CHEMOSENSITIZATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RNA INTERFERENCE; SURVIVAL TIME; SURVIVIN GENE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; METABOLISM; SCID MOUSE; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; CELL ADHESION MOLECULES; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG SYNERGISM; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; HETEROGRAFTS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE, SCID; NEOPLASTIC STEM CELLS; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84954484132     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11692     Document Type: Article

References (59)

1. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13(10): 714-26.
2. Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 2013; 32(1-2): 211-27.
3. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10): 883-92.
4. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013; 368(9): 842-51.
5. Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res. 2011; 17(15): 4942-7.
6. Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013; 332(2): 225-8.
7. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16): 5000-5.
8. Carter BZ, Qiu YH, Huang XL, et al. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012; 120(1): 173-80.
9. Lu X, Deng Q, Li H, Suo Z. Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy. Exp Ther Med. 2011; 2(5): 821-6.
10. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CHA. Treat cancers by targeting survivin: Just a dream or future reality? Cancer Treat Rev. 2013; 39(7): 802-11.
11. Zhou J, Bobbin ML, Burnett JC, Rossi JJ. Current progress of RNA aptamer-based therapeutics. Front Genet. 2012; 3: 234.
12. Xiang D, Shigdar S, Qiao G, et al. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics. 2015; 5(1): 23-42.
13. Cho EJ, Lee JW, Ellington AD. Applications of Aptamers as Sensors. Annu Rev Anal Chem. 2009; 2: 241-64.
14. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol. 2009; 27(9): 839-U95.
15. McNamara JO, 2nd, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24(8): 1005-15.
16. Shum KT, Zhou J, Rossi JJ. Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel). 2013; 6(12): 1507-42.
17. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012; 38(1): 68-75.
18. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010; 2(2): 129-36.
19. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17(3): 313-9.
20. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3): 1030-7.
21. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009; 8(10): 806-23.
22. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs. 2009; 1(1): 12-25.
23. McDermott M, Eustace AJ, Busschots S, et al. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Front Oncol. 2014; 4: 40.
24. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106(33): 13820-5.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7): 3983-8.
26. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci. 2003; 116(14): 2987-98.
27. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence. 2010; 1(1): 4.
28. Shigdar S, Qian C, Lv L, et al. The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer. PLoS One. 2013; 8(2).
29. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011; 102(5): 991-8.
30. Vercauteren D, Vandenbroucke RE, Jones AT, et al. The Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimization and Pitfalls. Mol Ther. 2010; 18(3): 561-9.
31. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007; 25(10): 1165-70.
32. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006; 107(2): 431-4.
33. Kleinman ME, Yamada K, Takeda A, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452(7187): 591-U1.
34. Robbins M, Judge A, Ambegia E, et al. Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation. Hum Gene Ther. 2008; 19(10): 991-9.
35. Gantier MP, Williams BRG. Monitoring Innate Immune Recruitment by siRNAs in Mammalian Cells. Rna Interference: From Biology to Clinical Applications. Methods Mol Biol. 2010; 623: 21-33.
36. Gantier MP, Tong S, Behlke MA, et al. Rational Design of Immunostimulatory siRNAs. Mol Ther. 2010; 18(4): 785-95.
37. Gantier MP, Williams BRG. The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev. 2007; 18(5-6): 363-71.
38. Marques JT, Devosse T, Wang D, et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol. 2006; 24(5): 559-65.
39. Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol. 2012; 21(2): 125-31.
40. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006; 17(4): 597-604.
41. Zhao YC, Wang Y, Ni XJ, et al. Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Mol Med Rep. 2014; 9(2): 614-20.
42. Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B. Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer. Clin Breast Cancer. 2011; 11(2): 129-34.
43. Aliabadi HM, Landry B, Mandipoor P, Uludag H. Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. Mol Pharmaceut. 2011; 8(5): 1821-30.
44. Guvenc H, Pavlyukov MS, Joshi K, et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res. 2013; 19(3): 631-42.
45. Hong SE, Kim EK, Jin HO, et al. S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin. Cell Biol Toxicol. 2013; 29(4): 273-82.
46. Zhang, M., et al. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Target Oncol. 2014. 9(4): 349-57.
47. Kreso A, van Galen P, Pedley NM, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014; 20(1): 29-36.
48. Perez J, Bardin C, Rigal C, Anthony B, Rousseau R, Dutour A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res 2011; 31(9): 2813-20.
49. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987; 84(9): 3004-8.
50. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. 2008; 129(2): 107-16.
51. Lee H, Lytton-Jean AK, Chen Y, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012; 7(6): 389-93.
52. Saggar JK, Yu M, Tan Q, Tannock IF. The tumor microenvironment and strategies to improve drug distribution. Front Oncol. 2013; 3: 154.
53. Martowicz A, Rainer J, Lelong J, Spizzo G, Gastl G, Untergasser G. EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth. Mol Cancer. 2013; 12: 56.
54. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011; 108(19): 7950-5.
55. Iliopoulos D, Hirsch HA, Wang GN, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011; 108(4): 1397-402.
56. Dahan P, Gala JM, Delmas C, et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis. 2014; 5.
57. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003; 8(5): 411-24.
58. Ntziachristos P, Lim JS, Sage J, Aifantis I. From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling. Cancer Cell. 2014; 25(3): 318-34.
59. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov. 2014; 13(7): 497-512.